UNSPSC 51112200: Combination antineoplastics

This classification denotes combination drugs that inhibit or prevent the proliferation of neoplasms, or proliferation of new abnormal growths of tissue, and which are therefore called ANTI-NEOPLASTICS or ANTINEOPLASTICS. Typical combination antineoplastic constituents are bleomycin, cyclophosphamide, doxorubicin, ifosfamide, methotrexate, and sodium chloride.

UNSPSC 51112200 Combination antineoplastics is a Class code covering multi-agent cancer chemotherapy drugs procured by state and local health systems, corrections departments, and public hospital networks. State and local governments buy combination antineoplastic formulations — typically injectable or oral chemotherapy regimens combining two or more active pharmaceutical agents — for oncology clinics, inpatient cancer wards, and correctional healthcare facilities. These purchases fall under pharmacy procurement and are often managed through group purchasing organizations, state health department formulary contracts, or hospital system cooperative purchasing agreements.

The source provided contains no recent state or local contract opportunities under this code. Without posted solicitations, geographic concentration, issuing-body patterns, and representative RFP, RFQ, IFB, or ITB records cannot be characterized from available data.